Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$0.34 - $0.86 $1,445 - $3,655
-4,250 Reduced 5.0%
80,790 $41,000
Q3 2021

Nov 15, 2021

SELL
$0.44 - $0.63 $66 - $94
-150 Reduced 0.18%
85,040 $38,000
Q2 2021

Aug 13, 2021

BUY
$0.48 - $0.72 $120 - $180
250 Added 0.29%
85,190 $52,000
Q1 2021

May 14, 2021

SELL
$0.68 - $1.25 $33,320 - $61,250
-49,000 Reduced 36.58%
84,940 $59,000
Q4 2020

Feb 12, 2021

SELL
$0.38 - $0.78 $1,900 - $3,900
-5,000 Reduced 3.6%
133,940 $91,000
Q3 2020

Nov 09, 2020

SELL
$0.47 - $0.64 $470 - $640
-1,000 Reduced 0.71%
138,940 $66,000
Q2 2020

Aug 13, 2020

SELL
$0.41 - $0.73 $1,193 - $2,124
-2,910 Reduced 2.04%
139,940 $72,000
Q1 2020

May 14, 2020

SELL
$0.36 - $0.79 $1,800 - $3,950
-5,000 Reduced 3.38%
142,850 $61,000
Q3 2019

Nov 13, 2019

BUY
$0.78 - $1.09 $60,723 - $84,856
77,850 Added 111.21%
147,850 $134,000
Q2 2019

Aug 09, 2019

BUY
$0.98 - $1.64 $6,860 - $11,480
7,000 Added 11.11%
70,000 $81,000
Q4 2018

Feb 07, 2019

BUY
$0.63 - $1.0 $630 - $1,000
1,000 Added 1.61%
63,000 $45,000
Q3 2018

Nov 14, 2018

BUY
$0.88 - $1.1 $27,280 - $34,100
31,000 Added 100.0%
62,000 $62,000
Q2 2018

Aug 14, 2018

BUY
$0.91 - $1.45 $2,730 - $4,350
3,000 Added 10.71%
31,000 $30,000
Q4 2017

Feb 14, 2018

BUY
$0.68 - $1.0 $8,836 - $12,995
12,995 Added 86.6%
28,000 $24,000
Q3 2017

Nov 14, 2017

SELL
$0.39 - $0.66 $3,900 - $6,600
-10,000 Reduced 39.99%
15,005 $10,000
Q2 2017

Aug 14, 2017

BUY
N/A
25,005
25,005 $11,000

Others Institutions Holding PTN

# of Institutions
1
Shares Held
2.94K
Call Options Held
0
Put Options Held
0

About PALATIN TECHNOLOGIES INC


  • Ticker PTN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,290,480
  • Market Cap $8.83M
  • Description
  • Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing o...
More about PTN
Track This Portfolio

Track Lpl Financial LLC Portfolio

Follow Lpl Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.